Business Segments · Total revenues
Business Segments — Total revenues
Neurocrine Biosciences Business Segments — Total revenues increased by 1.1% to $814.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 42.2%, from $572.60M to $814.50M. Over 3 years (FY 2022 to FY 2025), Business Segments — Total revenues shows an upward trend with a 24.3% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityStable
First reportedQ1 2022
Last reportedQ1 2026May 5, 2026
Rolls up toTotal Revenue
How to read this metric
An increase indicates successful commercialization and market penetration of the company's drug portfolio.
Detailed definition
Represents the total gross income generated by the company's primary business operations, including product sales and co...
Peer comparison
Standard revenue metric across all pharmaceutical peers, typically compared against consensus analyst estimates.
Metric ID:
nbix_segment_reportable_segment_total_revenuesHistorical Data
17 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $372.18M | $372.18M | $372.18M | $372.18M | $471.78M | $471.78M | $471.78M | $471.78M | $515.30M | $590.20M | $622.10M | $627.70M | $572.60M | $687.50M | $794.90M | $805.50M | $814.50M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +26.8% | +0.0% | +0.0% | +0.0% | +9.2% | +14.5% | +5.4% | +0.9% | -8.8% | +20.1% | +15.6% | +1.3% | +1.1% |
| YoY Change | — | — | — | — | +26.8% | +26.8% | +26.8% | +26.8% | +9.2% | +25.1% | +31.9% | +33.1% | +11.1% | +16.5% | +27.8% | +28.3% | +42.2% |
Range$372.18M – $814.50M
CAGR+21.6%
Avg YoY Growth+25.6%
Median YoY Growth+26.8%
Current Streak4 quarters growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's business segments — total revenues?
- Neurocrine Biosciences (NBIX) reported business segments — total revenues of $814.50M in Q1 2026.
- How has Neurocrine Biosciences's business segments — total revenues changed year-over-year?
- Neurocrine Biosciences's business segments — total revenues increased by 42.2% year-over-year, from $572.60M to $814.50M.
- What is the long-term trend for Neurocrine Biosciences's business segments — total revenues?
- Over 3 years (2022 to 2025), Neurocrine Biosciences's business segments — total revenues has grown at a 24.3% compound annual growth rate (CAGR), from $1.49B to $2.86B.
- What does business segments — total revenues mean?
- The total amount of money brought in from all business activities.